COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
Abivax annonce une mise à jour de son programme de développement clinique de phase 2b avec obefazimod dans la maladie de Crohn modérément à sévèrement active
Abivax annonce une mise à jour de son programme de développement clinique de phase 2b avec obefazimod dans la maladie de Crohn modérément à sévèrement active. L'initiation de l’inclusion des patients est prévue pour le troisième trimestre 2024, les données d'induction à 12 semaines sont attendues au deuxième semestre 2026 -
COMMUNIQUÉ DE PRESSE
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
Abivax updates obefazimod Phase 2b clinical program in Crohn’s disease following FDA feedback. Trial design modification to align with FDA recommendations. Patient enrollment to start in Q3 2024 -
-
-
COMMUNIQUÉ DE PRESSE
I-RES Welcomes ISS Recommendation to Vote AGAINST All Resolutions at Forthcoming EGM
Irish Residential Properties REIT plc welcomes ISS recommendation to vote against all resolutions at forthcoming EGM. The report issued by ISS recommends shareholders vote against all resolutions proposed by Vision Capital Corporation at the EGM on 16 February 2024 -
COMMUNIQUÉ DE PRESSE
Hawesko Group confirms sales and earnings expectations for 2023
Hawesko Group confirms sales and earnings expectations for 2023, achieving €660 million in sales and an operating result of approximately €34 million. The market conditions in 2023 were challenging due to consumer restraint, crises, and wars. Retail and B2B segments showed positive development, while e-commerce sales were -9% lower than the previous year. The Hawesko Group employed around 1,300 people across Retail, B2B, and e-commerce segments -
-
COMMUNIQUÉ RÉGLEMENTÉ
Saint-Gobain reinforces its building envelope protection offer in the United States
